Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Schmidt

Showing results (11-20 of 47) with videos related to

Pageof 5
Sort By:
Journal of Clinical Psychopharmacology|November 6, 2019
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute SchizophreniaDavid P Walling, Anindita Banerjee, Vikas Dawra, et al.
Psychopharmacology|April 20, 2010
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonistsBrooke M Roberts, Patricia A Seymour, Christopher J Schmidt, et al.
The Journal of Physiology|April 6, 2004
Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levelsMarzia Martina, Yelena Gorfinkel, Samantha Halman, et al.
Neuropharmacology|February 4, 2014
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implicationsSubramaniam Uthayathas, Gunasingh J Masilamoni, Christopher L Shaffer, et al.
Journal of Clinical Psychopharmacology|June 18, 2019
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of SchizophreniaNicholas DeMartinis, Rene N Lopez, Eve H Pickering, et al.
Neuropharmacology|December 7, 2007
Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic backgroundJudith A Siuciak, Sheryl A McCarthy, Douglas S Chapin, et al.
Neuroreport|February 27, 2010
Glycine transporter inhibition reverses ketamine-induced working memory deficitsBrooke M Roberts, Christopher L Shaffer, Patricia A Seymour, et al.
Neuropharmacology|September 22, 2009
Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10AChristine A Strick, Larry C James, Carol B Fox, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 21, 2011
Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF)Yanhua Zhang, F David Tingley, Elaine Tseng, et al.
Behavioural Brain Research|March 30, 2010
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunctionBrooke M Roberts, Daniel E Holden, Christopher L Shaffer, et al.
Pageof 5

Showing results (11-20 of 47) with videos related to

Sort By:
Pageof 5
Journal of Clinical Psychopharmacology|November 6, 2019
Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute SchizophreniaDavid P Walling, Anindita Banerjee, Vikas Dawra, et al.
Psychopharmacology|April 20, 2010
Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonistsBrooke M Roberts, Patricia A Seymour, Christopher J Schmidt, et al.
The Journal of Physiology|April 6, 2004
Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levelsMarzia Martina, Yelena Gorfinkel, Samantha Halman, et al.
Neuropharmacology|February 4, 2014
Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implicationsSubramaniam Uthayathas, Gunasingh J Masilamoni, Christopher L Shaffer, et al.
Journal of Clinical Psychopharmacology|June 18, 2019
A Proof-of-Concept Study Evaluating the Phosphodiesterase 10A Inhibitor PF-02545920 in the Adjunctive Treatment of Suboptimally Controlled Symptoms of SchizophreniaNicholas DeMartinis, Rene N Lopez, Eve H Pickering, et al.
Neuropharmacology|December 7, 2007
Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic backgroundJudith A Siuciak, Sheryl A McCarthy, Douglas S Chapin, et al.
Neuroreport|February 27, 2010
Glycine transporter inhibition reverses ketamine-induced working memory deficitsBrooke M Roberts, Christopher L Shaffer, Patricia A Seymour, et al.
Neuropharmacology|September 22, 2009
Alterations in gene regulation following inhibition of the striatum-enriched phosphodiesterase, PDE10AChristine A Strick, Larry C James, Carol B Fox, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|June 21, 2011
Development and validation of a sample stabilization strategy and a UPLC-MS/MS method for the simultaneous quantitation of acetylcholine (ACh), histamine (HA), and its metabolites in rat cerebrospinal fluid (CSF)Yanhua Zhang, F David Tingley, Elaine Tseng, et al.
Behavioural Brain Research|March 30, 2010
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunctionBrooke M Roberts, Daniel E Holden, Christopher L Shaffer, et al.
Pageof 5